カテゴリー： QYResearch, 世界, 医療/バイオ

世界の閉経後膣萎縮治療薬市場インサイト及び予測（エストロゲン系治療薬、非エストロゲン系治療薬）

◆英語タイトル：Global Postmenopausal Vaginal Atrophy Therapeutics Market Insights, Forecast to 2028
	◆商品コード：QY22JLX09277 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：111 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、閉経後膣萎縮治療薬のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に閉経後膣萎縮治療薬の世界市場のxxx％を占める「エストロゲン系治療薬」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
閉経後膣萎縮治療薬の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの閉経後膣萎縮治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

閉経後膣萎縮治療薬のグローバル主要企業には、Endoceutics、Accord Healthcare、Pfizer、Novo Nordisk、Teva Pharmaceuticals、Shionogi、Bionovo、QuatRx Pharmaceutical Company、Bayer AG、TherapeuticsMDなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

閉経後膣萎縮治療薬市場は、種類と用途によって区分されます。世界の閉経後膣萎縮治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
エストロゲン系治療薬、非エストロゲン系治療薬

【用途別セグメント】
病院、専門クリニック

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 閉経後膣萎縮治療薬製品概要
- 種類別市場（エストロゲン系治療薬、非エストロゲン系治療薬）
- 用途別市場（病院、専門クリニック）
- 調査の目的
・エグゼクティブサマリー
- 世界の閉経後膣萎縮治療薬販売量予測2017-2028
- 世界の閉経後膣萎縮治療薬売上予測2017-2028
- 閉経後膣萎縮治療薬の地域別販売量
- 閉経後膣萎縮治療薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別閉経後膣萎縮治療薬販売量
- 主要メーカー別閉経後膣萎縮治療薬売上
- 主要メーカー別閉経後膣萎縮治療薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（エストロゲン系治療薬、非エストロゲン系治療薬）
- 閉経後膣萎縮治療薬の種類別販売量
- 閉経後膣萎縮治療薬の種類別売上
- 閉経後膣萎縮治療薬の種類別価格
・用途別市場規模（病院、専門クリニック）
- 閉経後膣萎縮治療薬の用途別販売量
- 閉経後膣萎縮治療薬の用途別売上
- 閉経後膣萎縮治療薬の用途別価格
・北米市場
- 北米の閉経後膣萎縮治療薬市場規模（種類別、用途別）
- 主要国別の閉経後膣萎縮治療薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの閉経後膣萎縮治療薬市場規模（種類別、用途別）
- 主要国別の閉経後膣萎縮治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の閉経後膣萎縮治療薬市場規模（種類別、用途別）
- 主要国別の閉経後膣萎縮治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の閉経後膣萎縮治療薬市場規模（種類別、用途別）
- 主要国別の閉経後膣萎縮治療薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの閉経後膣萎縮治療薬市場規模（種類別、用途別）
- 主要国別の閉経後膣萎縮治療薬市場規模（トルコ、サウジアラビア）
・企業情報
Endoceutics、Accord Healthcare、Pfizer、Novo Nordisk、Teva Pharmaceuticals、Shionogi、Bionovo、QuatRx Pharmaceutical Company、Bayer AG、TherapeuticsMD
・産業チェーン及び販売チャネル分析
- 閉経後膣萎縮治療薬の産業チェーン分析
- 閉経後膣萎縮治療薬の原材料
- 閉経後膣萎縮治療薬の生産プロセス
- 閉経後膣萎縮治療薬の販売及びマーケティング
- 閉経後膣萎縮治療薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 閉経後膣萎縮治療薬の産業動向
- 閉経後膣萎縮治療薬のマーケットドライバー
- 閉経後膣萎縮治療薬の課題
- 閉経後膣萎縮治療薬の阻害要因
・主な調査結果

Postmenopausal vaginal atrophy (PVA), also referred to as postmenopausal atrophic vaginitis, caused by the vaginal walls’ drying, thinning, and inflammation due to reduced estrogen levels. Women with this disorder are more vulnerable to problems of urinary system and chronic infection of vaginal linings. A variety of medications and therapies available in market that focuses on the underlying cause as well as the symptoms of the condition. These therapies also helps women to improve their quality of life.
Market Analysis and Insights: Global Postmenopausal Vaginal Atrophy Therapeutics Market
The global Postmenopausal Vaginal Atrophy Therapeutics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Estrogen-based Drugs accounting for % of the Postmenopausal Vaginal Atrophy Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Postmenopausal Vaginal Atrophy Therapeutics market size is valued at US$ million in 2021, while the North America and Europe Postmenopausal Vaginal Atrophy Therapeutics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Postmenopausal Vaginal Atrophy Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Postmenopausal Vaginal Atrophy Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Postmenopausal Vaginal Atrophy Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Postmenopausal Vaginal Atrophy Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Postmenopausal Vaginal Atrophy Therapeutics market.
Global Postmenopausal Vaginal Atrophy Therapeutics Scope and Market Size
Postmenopausal Vaginal Atrophy Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Postmenopausal Vaginal Atrophy Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Estrogen-based Drugs
Non-estrogen-based Drugs
Segment by Application
Hospital
Specialist Clinic
By Company
Endoceutics
Accord Healthcare
Pfizer
Novo Nordisk
Teva Pharmaceuticals
Shionogi
Bionovo
QuatRx Pharmaceutical Company
Bayer AG
TherapeuticsMD
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Estrogen-based Drugs
1.2.3 Non-estrogen-based Drugs
1.3 Market by Application
1.3.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Specialist Clinic
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Perspective (2017-2028)
2.2 Postmenopausal Vaginal Atrophy Therapeutics Growth Trends by Region
2.2.1 Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Postmenopausal Vaginal Atrophy Therapeutics Market Dynamics
2.3.1 Postmenopausal Vaginal Atrophy Therapeutics Industry Trends
2.3.2 Postmenopausal Vaginal Atrophy Therapeutics Market Drivers
2.3.3 Postmenopausal Vaginal Atrophy Therapeutics Market Challenges
2.3.4 Postmenopausal Vaginal Atrophy Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Revenue
3.1.1 Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Postmenopausal Vaginal Atrophy Therapeutics Revenue
3.4 Global Postmenopausal Vaginal Atrophy Therapeutics Market Concentration Ratio
3.4.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Therapeutics Revenue in 2021
3.5 Postmenopausal Vaginal Atrophy Therapeutics Key Players Head office and Area Served
3.6 Key Players Postmenopausal Vaginal Atrophy Therapeutics Product Solution and Service
3.7 Date of Enter into Postmenopausal Vaginal Atrophy Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Postmenopausal Vaginal Atrophy Therapeutics Breakdown Data by Type
4.1 Global Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Type (2023-2028)
5 Postmenopausal Vaginal Atrophy Therapeutics Breakdown Data by Application
5.1 Global Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size (2017-2028)
6.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type
6.2.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022)
6.2.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028)
6.2.3 North America Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type (2017-2028)
6.3 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application
6.3.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022)
6.3.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028)
6.3.3 North America Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application (2017-2028)
6.4 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country
6.4.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022)
6.4.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size (2017-2028)
7.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type
7.2.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022)
7.2.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028)
7.2.3 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type (2017-2028)
7.3 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application
7.3.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022)
7.3.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028)
7.3.3 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application (2017-2028)
7.4 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country
7.4.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022)
7.4.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type
8.2.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type (2017-2028)
8.3 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application
8.3.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application (2017-2028)
8.4 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region
8.4.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size (2017-2028)
9.2 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type
9.2.1 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022)
9.2.2 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028)
9.2.3 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type (2017-2028)
9.3 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application
9.3.1 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022)
9.3.2 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028)
9.3.3 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application (2017-2028)
9.4 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country
9.4.1 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022)
9.4.2 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type
10.2.1 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type (2017-2028)
10.3 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application
10.3.1 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application (2017-2028)
10.4 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country
10.4.1 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Endoceutics
11.1.1 Endoceutics Company Details
11.1.2 Endoceutics Business Overview
11.1.3 Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.1.4 Endoceutics Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.1.5 Endoceutics Recent Developments
11.2 Accord Healthcare
11.2.1 Accord Healthcare Company Details
11.2.2 Accord Healthcare Business Overview
11.2.3 Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.2.4 Accord Healthcare Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.2.5 Accord Healthcare Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.3.4 Pfizer Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.3.5 Pfizer Recent Developments
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Details
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.4.4 Novo Nordisk Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.4.5 Novo Nordisk Recent Developments
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Details
11.5.2 Teva Pharmaceuticals Business Overview
11.5.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.5.4 Teva Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.5.5 Teva Pharmaceuticals Recent Developments
11.6 Shionogi
11.6.1 Shionogi Company Details
11.6.2 Shionogi Business Overview
11.6.3 Shionogi Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.6.4 Shionogi Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.6.5 Shionogi Recent Developments
11.7 Bionovo
11.7.1 Bionovo Company Details
11.7.2 Bionovo Business Overview
11.7.3 Bionovo Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.7.4 Bionovo Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.7.5 Bionovo Recent Developments
11.8 QuatRx Pharmaceutical Company
11.8.1 QuatRx Pharmaceutical Company Company Details
11.8.2 QuatRx Pharmaceutical Company Business Overview
11.8.3 QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.8.4 QuatRx Pharmaceutical Company Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.8.5 QuatRx Pharmaceutical Company Recent Developments
11.9 Bayer AG
11.9.1 Bayer AG Company Details
11.9.2 Bayer AG Business Overview
11.9.3 Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.9.4 Bayer AG Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.9.5 Bayer AG Recent Developments
11.10 TherapeuticsMD
11.10.1 TherapeuticsMD Company Details
11.10.2 TherapeuticsMD Business Overview
11.10.3 TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.10.4 TherapeuticsMD Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.10.5 TherapeuticsMD Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の閉経後膣萎縮治療薬市場インサイト及び予測（エストロゲン系治療薬、非エストロゲン系治療薬）(Global Postmenopausal Vaginal Atrophy Therapeutics Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の閉経後膣萎縮治療薬市場インサイト及び予測（エストロゲン系治療薬、非エストロゲン系治療薬）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp